Holderried, Tobias A. W. and Fraccaroli, Alessia and Schumacher, Martin and Hein, Annkristin and Brossart, Peter and Stelljes, Matthias and Klobuch, Sebastian and Kroeger, Nicolaus and Apostolova, Petya and Finke, Juergen and Zeiser, Robert and Heinicke, Thomas and Bornhaeuser, Martin and Von Bergwelt-Baildon, Michael and Tischer, Johanna and Wolf, Dominik (2019) The role of checkpoint blockade after allogeneic stem cell transplantation in diseases other than Hodgkin's Lymphoma. BONE MARROW TRANSPLANTATION, 54 (10). pp. 1662-1667. ISSN 0268-3369, 1476-5365
Full text not available from this repository. (Request a copy)Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HSCT) is the only curative treatment option for many malignant high-risk hematological diseases. The Graft-vs.-Tumor (GvT) effect is the major hallmark of this treatment approach. However, disease relapse remains a major limitation. Boosting the GvT effect by checkpoint inhibitors (CI) is an attractive option in this desperate situation although potentially triggering Graft-vs.-Host Disease (GvHD). Early reports in patients with Hodgkin's lymphoma support the idea that CI therapy after HSCT is feasible and effective. We have retrospectively analyzed CI therapy for treatment of disease recurrence after allo-HSCT other than Hodgkin's lymphoma including 21 patients from eight German transplant centers. The median follow-up was 59 days. The overall response rate (ORR) was 43%. Patients receiving donor lymphocyte infusion (DLI) in combination with CI had superior response (ORR 80%). Severe acute GvHD grade III-IV and moderate to severe chronic GvHD were observed in 29% of all patients. Taken together, CI therapy in relapsed patients after HSCT, especially in combination with DLI, is effective but induces severe GvHD in a considerable proportion of patients. Thus, prospective trials or EBMT registry-based validation of different dosing and application schedules including immunosuppressive regimens in those patients are urgently needed.
| Item Type: | Article |
|---|---|
| Uncontrolled Keywords: | PD-1 BLOCKADE; RELAPSE; IPILIMUMAB; NIVOLUMAB; |
| Subjects: | 600 Technology > 610 Medical sciences Medicine |
| Divisions: | Medicine > Lehrstuhl für Innere Medizin III (Hämatologie und Internistische Onkologie) |
| Depositing User: | Dr. Gernot Deinzer |
| Date Deposited: | 30 Mar 2020 12:51 |
| Last Modified: | 30 Mar 2020 12:51 |
| URI: | https://pred.uni-regensburg.de/id/eprint/26155 |
Actions (login required)
 |
View Item |
